GFRP revoked:

https://www.sec.gov/litigation/admin/2016/34-78688.pdf

GFRP SEC Suspension for Financials / Filings delinquencies:

https://www.sec.gov/litigation/suspensions/2016/34-77867.pdf

Order:

https://www.sec.gov/litigation/suspensions/2016/34-77867-o.pdf

Admin Proceeding:

https://www.sec.gov/litigation/admin/2016/34-77866.pdf

GFRP is smells like a winner

No idea, wish I still owned it !!!

how did it get to $.74?

Check now ...

Nice volume here, moving up !!!

The chromatograph market worldwide is 5 billion dollars. In sharp contrast the market in China today it is only 10 million.

sitting 4 cents on bid is a shame.....with all that they offer, it should trade much higher

These leading brands include:
Kramasil in Switzerland
Waters & Varian in the US.A
Toyota in Japan
And Hypersil in the U.K.

I belioeve they hold the market monopoly for the chromatograph technology in China. The technology will belike 30 competitors in this field worldwide. The evidence to this claim is verified in R&D studies recently conducted in the U.S.

ots profits were generated from their PET and gamma knife business and directly fund their core business in the Research and Development of their chromatograph technology.

they must have evolved over the years...

2 core businesses, 1 PET scanner,Gamma Knife at a Center and then another part, products, see filings :

The Company’s business units have been aggregated into two reportable segments, as defined by SFAS 131:

· Medical Business - joint operation of PET Scanner and Rotary Gamma Ray Stereotactic Neurosurgery System imaging center in the PRC.


· Extraction Business - extraction of raw materials to medicine ingredients and distribution of extracted ingredients for medicine manufacturing uses.

what kind of business do they have in it currently?

It is tightly held ...hope she rises

This is a Chinese stock that has been sitting here for a long time....I wonder what will happen to the company?

Revenues

Through the second quarter of 2009, we continued to realize our revenues from the business operations of two subsidiaries: New Century and Bao Sai. New Century owns radiology and oncology equipment and provides it to Tangdu Hospital’s Gamma Knife Therapeutic Center (the “Center”) in Shaan Xi province, which is affiliated with the Fourth Military Medical University. New Century currently owns three different devices used for radiological imaging for the brain and body and cancer treatment. New Century receives a percentage of profits from the Center. We recognize net revenues based on the total amount received from the patients during the month, less the monthly operating costs incurred at the centers. The service revenues were recorded when services are received by the customers and realized the amounts net of provisions for discounts, allowance and taxes which are recognized at the time of services performed.


2


The revenue from our operation of the Center decreased from $1,503,258 for the quarter ended June 30, 2008 to $973,621 for the same period of 2009 and. decreased from $1,978,953 during the six months ended June 30, 2008 to $ 1,527,877 during the six months ended June 30, 2009. During the second quarter of 2009, the Center, on average handled approximately 217 cases per month, compared to 188 cases per month in the same period of 2008. Revenues from our operation of the Center declined, despite more cases, in part because the respective profit sharing ratios between us and the Center changed. New Century receives 70% of the revenues of the Centers in 2009 compared to 80% in 2008. Similarly, our production sales from our Bao Sai subsidiary also decreased from $623,568 during the six months ended June 30, 2008 to $19,165 during the six month ended June 30, 2009. Baosai’s revenue decrease so much from 2008 to 2009 principally as a result of the financial crisis affecting its customers. .

As a result, our overall revenues for the second quarter of 2009 slightly decreased to $983,000 from $1,539,313 for the same period ended June 30, 2009. Likewise, our overall revenue decreased from $2,221,720 during the six months ended June 30, 2008 to $1,547,042 during the six months ended June 30, 2009. This decrease was attributed to our business adjustment after our acquisition of a new subsidiary Bao Sai in August 2008. Our Bao Sai operation was still in a developmental stage. We expect it will put us in a stronger position for increasing our market share and revenue later in 2009 because we believe the market for its services provides significant opportunities for growth.

Expenses

Accordingly, our operating expenses for the second quarter of 2009 was reduced to $360,578, a decrease of $164,080 or 31% from $524,658 for the same period of 2008. Our operating expenses during the six months ended June 30, 2009 was reduced to $748,990, a decrease of $ 150,189 or 16.7% to $ 899,179 during the six months ended June 30, 2008. The reduction in our operating expenses was due primarily to the decrease of our business scope and scale as a result of our acquisition of Bao Sai in August 2008, despite of the increased number of our full time employees by about 52 as of June 30, 2009 as a result of the acquisition.

Net Income

Our net income during the three and six months ended June 30, 2009 was $444,346 and $553,770 respectively, compared to $752,803 and $909,484 during the three and six months ended June 30, 2008. The reduction of our net income was primarily due to our decreased revenue as a result of our business adjustment after our acquisition of Bao Sai. As we complete our business adjustment and our operation of Bao Sai expands in the future, we expect our net income to increase.

We expect to be profitable during fiscal year 2009 through the implementation of our marketing strategies. However, we cannot be certain that we will be able to successfully implement our marketing strategies and revenues may decline in 2009 compared to 2008 or, therefore, that we will be profitable.

Impact of Inflation

We believe that inflation has had a negligible effect on operations during this period. We believe that we can offset inflationary increases in the cost of sales by increasing sales and improving operating efficiencies.

Our business operates entirely in Chinese Renminbi, but we report our results in our SEC filings in U.S. Dollars. The conversion of our accounts from RMB to Dollars results in translation adjustments. While our net income is added to the retained earnings on our balance sheet; the translation adjustments are added to a line item on our balance sheet labeled “other comprehensive income,” since it is more reflective of changes in the relative values of U.S. and Chinese currencies than of the success of our business. During the six and three months ended June 30, 2009, the effect of converting our financial results to Dollars was to add $125 and $40 to our comprehensive income.


3


LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2009, cash in the bank decreased to $18,326, compared to $552,398 as of December 31, 2008. This decline is primarily due to repayment of $1,344,846 of notes payable to related parties arising from the acquisition of Bao Sai. Our Cash flows provided by operating activities were $1,031,419 for six months ended June 30, 2009; a significant increase of $821,421 or 391% compared to cash flows of $209,998 from operating activities for the same period ended June 30, 2008. The increase in the positive cash flows from operations for the first six months of 2009 was due primarily to the substantial increase of collected accounts receivable of $53,576 from ($ 264,322) for the six months of 2008, and substantial reduction of our trade accounts payable to ($74,159) for the first six months of 2009 from ($887,603) for the same period of 2008.

However, cash flows used in investment activities were $(1,344,846) for the six months ended June 30, 2009, which was used to repay the notes payable to related parties. .Meanwhile, cash flows used in financing activities were $(220,733) for the six months ended June 30, 2009.

Our stockholders’ equity increased from $2,712,927 at December 31, 2008 to $3,235,654 at June 30, 2009.

In connection with the purchse of Bao Sai, we still have a note payable in the amount of $1,149,277 due on December 31, 2009 for the balance of the purchase price. We may not be able to generate sufficient cash to satisfy this obligation from internally generated funds. In such event, we would need to obtain funds from related parties or outside sources or seek to renegotiate the terms of the loan, of which there can be no assurance.

In addition, allowance for doubtful accounts receivable was $515,230 as of June 30, 2009 ($515,026 recorded as a doubtful account receivable on December 31, 2008) with total accounts receivable totaling $1,121,237, compared to $1,196,511 as of June 30, 2008. The inability to collect more outstanding receivables can adversely affect our operations. The Center accounted for 81% of our accounts receivable as of June 30, 2009.

On September 3, 2007, the Company’s newly acquired subsidiary, Bao Sai, disposed of its investment in 75% of HuaYang for a cash consideration of $1,097,358 (equivalent to RMB7, 500,000). The balance was unsecured and interest-free and repayable in 4 installments due in full, by December 31, 2008. However, the balance was overdue as of December 31, 2008, and additional agreement was entered into by both parties to extend the payment term up to December 31, 2009. As collectibility has been considered doubtful, an allowance of doubtful debt was made fully on the notes receivable. The failure of the Company to collect this receivable has adversely affected the Company’s liquidity.

We also advanced to Xi’an Bao Sai Medicine Co., Ltd (“Medicine”) a loan in the principal amount of $1,103,046 which was unsecured and interest-free. The loan is repayable in four equal annual installments commencing December 31, 2009 through December 31, 2012. The Company leased Bao Sai’s business license for an annual fixed return. Bao Sai has a 75% equity interest in Medicine.

Someone buying up shares, trying to not sound alarms ...

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6470407

Quarterly/Yearly report Filed ..

The number of shares of common stock, no par value per share, outstanding as of August 11, 2009 was 42,079,940

Update Quarterly Report Filed ...

http://ih.advfn.com/p.php?pid=nmona&cb=1242312808&article=37710562&symbol=NB^GFRP

42 million shares, tightly held ... Overseas company

Spoke today with Canadian GFR Pharm CEO, Richard Pierce, who says they have nothing to do with the new Overseas company

He said they have been filing regularly and the shares are tightly held in his opinion

I told him I would dig further and let us know what is up with this company

GFRP picked up the dreaded "E" today...

Now GFRPE

On January 5, 2009, the Company engaged Yu and Associates CPA Corporation (“Yu and Associates”) as Company’s new independent accountants. At no time during the past two fiscal years or any subsequent period prior to the engagement did the Company consult with Yu and Associates, the newly engaged accountant, regarding any matter described in Item 304(a)(2) of Regulation SK, including any issue related to Company’s financial statements or the type of audit opinion that might be rendered for the Company.


On January 5, 2009, the Company’s former independent accountants, Zhong Yi (Hong Kong) C.P.A. Company Limited (“Zhong Yi”) were dismissed as independent accountants of the Company. The change of independent accountants was approved by the Board of Directors of the Company .


The former independent accountant’s reports on the Company’s financial statements for the last two fiscal years did not contain any adverse opinions or disclaimer opinions, nor were the reports qualified or modified as to uncertainty, audit scope or accounting principles.

Furthermore, the accountant’s reports did not include any disclosure of uncertainty regarding the Company’s ability to continue as a going concern.


During the Company’s last two fiscal years and through the date of dismissal, there were no disagreements between the Company and its former independent accountants on any matters relating to accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of the former independent accountants, would have caused them to make reference to the subject matter of the disagreement in their report.


The Company requested Zhong Yi to furnish a letter addressed to the Securities and Exchange Commission stating whether or not Zhong Yi agrees with the statements in this 8-K. A copy of such letter is filed as exhibit 16.1 to this 8-K

YES, we are in demand !!!!

Ok, who's got the paintbrush...lol

100 shares at .4888 for a 1529% increase today...gave me a friggin heart attack!!!

Looks like someone got tired of holding...20K just sold...

New Auditor engaged, maybe time for an uplist ? You never know ...


Form 8-K GFR PHARMACEUTICALS INC For: Jan 05

11:35 AM EST January 7, 2009
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6061956

Filed on: January 7, 2009

New Financials Look AWESOME


http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5989506


GFR PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2008
(Currency expressed in United States Dollars (“US$”), except for number of shares)
(Unaudited)



Common stock

Additional Accumulated
other
comprehensive Statutory Retained Total
Stockholders’
No. of shares Amount paid-in capital income reserve earnings equity

Balance as of January 1, 2008 42,079,940 $ 42,080 $ 3,712,120 $ 134,797 $ 236,818 $ 1,552,501 $ 5,678,316

Foreign currency translation adjustment - - - 506,694 - - 506,694

Net income for the period - - - - - 1,381,129 1,381,129

Balance as of September 30, 2008 42,079,940 $ 42,080 $ 3,712,120 $ 641,491 $ 236,818 $ 2,933,630 $ 7,566,139



See accompanying notes to condensed consolidated financial statements.

Financials look awesome ... http://finance.yahoo.com/q/is?s=gfrp.ob

picked up some cheapies today !!!

no, Canada

Aren't they located in China?

Supernatural British Columbia Home to GFR Pharma

Located near the magnificent mountain vistas of Golden Ears National Park, GFR Pharma operates its private label manufacturing facility and corporate offices in its own 10,000 square foot building. Only 20 miles east of Vancouver, GFR's location is within easy access to downtown Vancouver and the entire lower mainland. Out-of town visitors to GFR often take advantage of the opportunity to visit the world-renowned ski resort and village of Whistler or take a trip on BC Ferries to the beautiful Gulf Islands located off the coast of Vancouver.

GFR Pharma
Contact Information

11450-201A Street, Maple Ridge
British Columbia, Canada VV2X 0Y4

Toll Free: 1-877-560-8440
Phone: (604) 460-8440 FFax: (604) 648-8221

website: www.gfrpharma.com
email: sales@gfrpharma.com

Meet the GFR Professionals

GFR Pharma’s management team combines extensive pharmaceutical, vitamin, mineral, and herbal knowledge with strategic business expertise. Our team of capable professionals in the areas of manufacturing, quality assurance, research and development, distribution, sales, finance, graphics and marketing can help you every step of the way… from concept to reality.

Richard Pierce, President & CEO
Richard Pierce is a respected member of the Canadian Health Food Association. Richard is well known in the natural products industry for creating and marketing the most successful brand of sports nutrition products in Canada. Long before most people had even heard of whey or soy protein powders, Richard was researching and developing products to support health and fitness. Richard has nearly 25 years of experience in the natural health industry. During this time he has consistently identified emerging market trends and created an organization that is recognized as an innovative, high quality manufacturer.

Mark Likness, General Manager
Mark Likness has successively been the General Manager and Vice President of Sales and Marketing of GFR Pharma since January 2003. With over 20 years experience in sales, marketing, and distribution in the pharmaceutical and natural health industries, Mark provides the organization with strong leadership. Prior to joining GFR Pharma, Mark held the positions of Director of Logistics, Director of Business Development, National Sales Manager, and Western Regional Manager with Stanley Pharmaceuticals.

Marc Casavant, Chief Financial Officer
Marc Casavant has been the Chief Financial Officer of GFR Pharma since April, 2000. Marc has over 11 years of financial management experience in the natural products industry and 19 years experience in the accounting field. His extensive accounting background in the health sector provides him with a unique understanding of the cost accounting practices within a manufacturing environment

Maribel Aloria, Director of Quality Control
Maribel Aloria has been the Director of Quality Control since February, 2003. Maribel has a Bachelor of Science in Chemistry and a Masters of Management Technology. Prior to joining GFR Pharma, she was involved in the implementation of ISO 9000 (Quality Management System) and ISO 14000 (Environmental Management System) in the quality assurance and quality control departments of Siemens and Health Canada. Maribel’s experience and diversified scientific background has contributed to the organization’s compliance to Health Canada’ s Food and Drugs Act and Regulations, Natural Health Products Regulation and their corresponding Good Manufacturing Practices. At GFR Pharma, Maribel has been instrumental in the issuance of Establishment Licenses, Site License, Precursor License and Product Licenses (NPN, DIN).

RoseMarie Pierce, Holistic Pharmacist
RoseMarie Pierce is a Dalhousie University graduate who has practiced Pharmacy in Nova Scotia and Alberta for more than 30 years. Proficient in the fields of phyto-pharmacy, herbal medicine, holistic health and nutrition, RoseMarie provides extensive experience to the GFR team. In her capacity as Holistic Pharmacist, RoseMarie advises on product formulation, contributes to corporate training programs and provides consumer education. With a focus on hormonal health, RoseMarie is a regular contributor to health and nutrition magazines, a spokesperson within the natural products industry, and a frequent guest on radio and television.

John Speers, Research & Development Manager
John Speers has been with GFR Pharma since August 1999. John studied in the field of Business Administration at Douglas College. Prior to becoming the Manager of Research and Development in 2002, John has held various roles at GFR Pharma including purchasing, quality assurance, and production. John’s extensive production experience has provided him an in depth understanding of the challenges involved with the formulation of tablets, capsules and powders.

Sam Elliott, Graphic Designer
Sam Elliott comes to GFR Pharma with nine years of graphic design experience. Sam has a Multimedia Certificate from the University of British Columbia and a Graphic Design Certificate from Burnaby College. Prior to joining GFR Pharma in May 2005, Sam owned and operated a successful Graphic Design business for over four years. His background includes packaged goods, magazines, brochures and websites.

http://www.gfrpharma.com/gfr4.html

GFR Commitment to Quality Assurance
and Proof Potency
http://www.gfrpharma.com/gfr3.html

At GFR Pharma we give you every reason to feel proud and confident in the quality of your products made by our company. We know how critically important Quality Assurance and Proof of Potency is to the success of your product and your company's reputation.

That's why GFR Pharma subjects all raw materials and finished products to stringent test criteria and validation protocols of the highest order. GFR takes the necessary steps to ensure the quality and potency of every private label product we manufacture.

We also know that consumer concerns over the quality and potency of many nutritional products is entirely justified. Consumers have learned that all too often laboratory reports reveal the truth of the matter: what's on the label is not always what's in the bottle.

"If it's on the label, it's in the bottle".

The GFR Quality Assurance program starts even before we order or receive the raw materials we use to make your products. To begin with, the suppliers of all your formula's ingredients send a Certificate of Analysis for each and every ingredient we plan to order to the GFR Quality Control Director.

After reviewing the Certificate of Analysis provided by the supplier, the Quality Control Director approves or rejects the ordering of the ingredients based upon their meeting the quality and potency specifications for the product.

But we don't stop there...

GFR Pharma takes the necessary steps to ensure the quality and potency of every private label product we manufacture.

Every single ingredient that arrives at the GFR facility goes immediately into the GFR Quarantine Area. A sample of the raw material is taken from every shipment and sent to an independent laboratory for testing. Absolutely no use or removal of the raw materials is allowed until the laboratory report confirms or rejects the identity, potency and safety of the raw materials.

But we don't stop there...

Each ingredient is tested by an independent laboratory.

Each and every raw material ingredient is tested by an independent laboratory to test for accurate identity (the product is what it's supposed to be); to test for quality and purity (there are no bacteria or other contaminants); and to test for potency (the strength and potency of this material is what it claims to be). To ensure complete impartiality, the laboratories used by GFR Pharma are all government-approved, independent laboratories with absolutely no financial or personal links to GFR Pharma.

All testing facilities used by GFR Pharma are government-approved, independent laboratories.

Once your private label product is formulated, blended, encapsulated, packaged, and safety-sealed, GFR Pharma once again sends your sealed product to an independent laboratory for finished product testing.

But we don't stop there...

GFR Pharma retains sample bottles of your safety-sealed products for future stability testing to guarantee the stated shelf life of your product. Now that's commitment!




Home | About GFR | Quality Assurance & Proof of Potency | The GFR Professionals
GFR Services | Product List A - Z | Contact Information | Request Form | E-mail GFR

About GFR Pharma

http://www.gfrpharma.com/gfr6.html

GFR Pharma is a full service private label manufacturing facility specializing in the production of natural-source nutritional, herbal, and sports nutrition products. Every step along the way - from obtaining the best quality ingredients to independent laboratory assays on raw materials and finished products, GFR Pharma provides a full range of in-house manufacturing services to private label customers.

Formulating
Blending
Encapsulating
Powders
Packaging
Raw Material Sourcing
Raw Material Testing
Finished Product Testing
Technical Support
Market Research
Label Design & Production
DIN (Drug Identification Number)


The GFR Pharma manufacturing facility produces high-quality nutritional products in capsule and powder form. GFR specializes in the production of:
Vitamins & Supplements
Herbs & Herbal Formulas

Indication Specific Health Formulas

Women's Health
Men's Health
50+
Sports & Fitness
Weight Management

Minerals
Hormones
Enzymes
Amino Acids


The GFR Customer Service Promise

At GFR Pharma, we promise to provide high-quality nutritional products that have been purity and potency tested by independent laboratories. All this at the most economical prices available.

FORMULATING

GFR's expert advisors are always ready and willing to help.
We begin the important formula design process by listening closely to the client's ideas and goals, focusing on designing a product that meets the function and use criteria of the finished product's target market. The GFR team of expert advisors will assist in the research and formulation of nutritional, herbal and sports nutrition products. We formulate and design product prototype samples based upon the required nutritional profile, and ingredient specifications.





Watch Movies for FREE, Full Screen DVD Quality Movies Online. SuperBad,SpiderMan 3,SurfsUp,etc. http://www.reeltime.com/reelcash/

in ...

1st post to this lonely site!